Search

Your search keyword '"Salvatore Contini"' showing total 2 results
Start Over Author "Salvatore Contini" Journal annals of hematology
2 results on '"Salvatore Contini"'

1. Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura

Author

Salvatore Contini, Claudio Fozza, Simonetta Pardini, Antonella Isoni, Tatiana Marras, Francesco Longu, and Maurizio Roberto Longinotti

Subjects
medicine.medical_specialty, Platelet Aggregation, Platelet aggregation, Recombinant Fusion Proteins, Receptors, Fc, Immune system, Internal medicine, medicine, Humans, Platelet, Diagnostic Errors, Edetic Acid, Aged, Purpura, Thrombocytopenic, Idiopathic, Hematology, Romiplostim, Platelet Count, business.industry, Anticoagulants, General Medicine, medicine.disease, Thrombocytopenia, Thrombocytopenic purpura, Purpura, Thrombopoietin, Pseudothrombocytopenia, Immunology, Female, medicine.symptom, business, medicine.drug
Published
2013
Full Text
View/download PDF

2. Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma

Author

Maurizio Roberto Longinotti, Domenica Barbara Giannico, Salvatore Contini, Silvana Bonfigli, Antonio Galleu, Claudio Fozza, and Maria Grazia Careddu

Subjects
medicine.medical_specialty, Hematology, biology, business.industry, Anemia, Chronic lymphocytic leukemia, General Medicine, medicine.disease, hemic and lymphatic diseases, Internal medicine, Immunology, Monoclonal, biology.protein, Medicine, Rituximab, Splenic marginal zone lymphoma, Autoimmune hemolytic anemia, Antibody, business, medicine.drug
Abstract

Autoimmune manifestations including autoimmune hemolytic anemia (AIHA) are often described in association with splenic marginal zone lymphoma (SMZL) [1]. Moreover, AIHA has been recently reported as a potential risk factor of poor outcome for SMZL patients [2]. Among the different available therapeutic options, rituximab monotherapy has been recently shown to be extremely effective in SMZL [3]. On the other hand, this monoclonal antibody plays a key role in the treatment of steroid-refractory AIHA [4]. More specifically, although rituximab has been recently included among the possible strategies to treat AIHA secondary to chronic lymphocytic leukemia [5], very few cases describing its use in the course of SMZL-related AIHA have been described so far [6].

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results